CIK 0001357459 · Non-accelerated filer<br>Smaller reporting company
PALISADE BIO, INC.
Sign in to watch- Ticker
- PALI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522007292
- Phone
- (858) 704-4900
- Business address
- 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
- Former names
- PALISADE BIO, INC., Seneca Biopharma, Inc., Neuralstem, Inc.
- Open-market buys, last 90 days
- $28,800
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$28,800. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-19 | Capers Julien E. See Remarks | Grant or award | +787,300 | 787,300 | ||
| 2026-10-06 | Jones Mitchell Lawrence See Remarks | Option exercise | +2,620,850 | 2,714,859 | ||
| 2026-10-06 | Jones Mitchell Lawrence See Remarks | Shares withheld for taxes | −1,031,102 | $1.49 | $1.5M | 1,683,757 |
| 2026-10-06 | Jones Mitchell Lawrence See Remarks | Option exercise · Restricted Stock Units | −2,555,266 | 5,110,534 | ||
| 2026-10-06 | Jones Mitchell Lawrence See Remarks | Option exercise · Restricted Stock Units | −65,584 | 590,249 | ||
| 2026-10-06 | Finley John David CEO CFO | Option exercise | +3,227,384 | 3,356,672 | ||
| 2026-10-06 | Finley John David CEO CFO | Shares withheld for taxes | −1,411,982 | $1.49 | $2.1M | 1,944,690 |
| 2026-10-06 | Finley John David CEO CFO | Option exercise · Restricted Stock Units | −3,059,800 | 6,119,600 | ||
| 2026-10-06 | Finley John David CEO CFO | Option exercise · Restricted Stock Units | −167,584 | 1,508,249 | ||
| 2026-10-02 | Williams Donald Allen Director | Purchase | +10,000 | $1.46 | $15K | 1,590,294 |
| 2026-10-01 | Williams Donald Allen Director | Purchase | +10,000 | $1.42 | $14K | 1,580,294 |
| 2026-08-19 | Finley John David CEO, CFO | Gift | −88,400 | 129,288 | ||
| 2026-08-19 | Finley John David CEO, CFO | Gift | +88,400 | 88,451 | ||
| 2026-07-09 | Baltera Robert Jr. Director | Purchase | +25,000 | $1.96 | $49K | 461,904 |
| 2026-07-08 | Baltera Robert Jr. Director | Purchase | +20,000 | $1.99 | $40K | 436,904 |
| 2026-07-07 | Baltera Robert Jr. Director | Purchase | +30,000 | $2.03 | $61K | 416,904 |
| 2026-07-07 | Jones Mitchell Lawrence Chief Medical Officer | Sale | −51,880 | $2.05 | $107K | 94,009 |
| 2026-07-07 | Finley John David CEO, CFO | Sale | −146,798 | $2.07 | $303K | 217,555 |
| 2026-07-07 | Finley John David CEO, CFO | Option exercise | +133 | $0.70 | $93 | 217,688 |
| 2026-07-07 | Finley John David CEO, CFO | Option exercise · Series 2 Common Stock Purchase Warrant | −133 | 0 |
Page 1 of 12 · 233 trades